Intellia Therapeutics, Inc.
http://www.intelliatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Intellia Therapeutics, Inc.
Intellia Becomes First To Show Potential For CRISPR Therapy Re-Dosing
The company presented data showing it is possible to safely and effectively re-dose its ATTR amyloidosis CRISPR/Cas9-based therapy.
Alnylam’s Amvuttra Market May See Tenfold Increase After Phase III Win
The company posted positive results from the HELIOS-B trial in patients with ATTR-CM, which represents a much larger population than the approved hATTR-PN indication.
Intellia Builds Case For NTLA-2002’s Functional Cure In Angiodema
The hereditary angioedema candidate could become the first ever in vivo gene-editing therapy – but whether it will truly transform treatment remains to be seen.
Verve Not Ready To Pull Plug On Anti-PCSK9 Gene Editing Candidate
The company told Scrip that the sixth patient with elevated liver enzymes and low platelets recovered after hospital observation and oral steroids, and it may still continue VERVE-101’s development.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- ADMET
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Caribou Biosciences
- eXtellia
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice